VERVVerve Therapeutics, Inc.

Nasdaq vervetx.com


$ 6.26 $ -0.06 (-0.95 %)    

Monday, 29-Apr-2024 10:19:03 EDT
QQQ $ 432.59 $ -0.56 (-0.13 %)
DIA $ 383.60 $ 0.25 (0.07 %)
SPY $ 510.32 $ 0.06 (0.01 %)
TLT $ 88.60 $ -0.07 (-0.08 %)
GLD $ 216.28 $ 0.22 (0.1 %)
$ 6.16
$ 6.32
$ 0.00 x 0
$ 0.00 x 0
$ 6.23 - $ 6.41
$ 6.02 - $ 21.42
791,566
na
395.32M
$ 2.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-27-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-02-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-14-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 cathie-woods-ark-invest-sheds-64m-worth-of-coinbase-shares-despite-positive-market-movements-analyst-upgrade

On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite...

 stifel-maintains-buy-on-verve-therapeutics-lowers-price-target-to-40

Stifel analyst Dae Gon Ha maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and lowers the price target from $56 to $40.

 nasdaq-down-over-1-vivopower-international-shares-spike-higher

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down ...

 why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

 gene-therapy-side-effects-verve-therapeutics-halts-enrollment-of-lead-gene-therapy-trial-in-patients-with-bad-cholesterol

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regul...

 crude-oil-surges-over-1-us-factory-orders-increase-in-february

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded dow...

 verve-therapeutics-announces-updates-on-pcsk9-program-company-to-pause-enrollment-in-heart-1-clinical-trial-following-asymptomatic-grade-3-transient-alt-elevation-and-thrombocytopenia-seen-in-sixth-participant-enrolled-in-045-mgkg-dose-cohort

VERVE-101 is being evaluated in the Heart-1 Phase 1b clinical trial with trial endpoints of safety and tolerability as well as ...

 rbc-capital-reiterates-outperform-on-verve-therapeutics-maintains-35-price-target

RBC Capital analyst Luca Issi reiterates Verve Therapeutics (NASDAQ:VERV) with a Outperform and maintains $35 price target.

 verve-therapeutics-q4-gaap-eps-069-beats-082-estimate-sales-514m-beat-117m-estimate-cash-cash-equivalents-and-marketable-securities-of-624m-with-cash-runway-into-late-2026

Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(...

 18m-bet-on-verve-therapeutics-check-out-these-3-stocks-insiders-are-buying

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

 why-patterson-companies-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than...

 why-verve-therapeutics-stock-verv-is-falling

Verve Therapeutics Inc (NASDAQ: VERV) shares are trading lower by 6.3% to $11.18 Wednesday morning after the company priced its...

 why-workday-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket

Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION